IL6 and COVID-19: Although blocking IL-6 signalling as a therapeutic intervention has been extensively studied in other diseases53,54, randomised controlled clinical trials with biologics targeting the IL-6 receptor, including Tocilizumab, have already shown some evidence of clinical benefit in COVID-19 cases55–58.